Related Experiment Video

Updated: Aug 1, 2025

Large Scale Non-targeted Metabolomic Profiling of Serum by Ultra Performance Liquid Chromatography-Mass Spectrometry UPLC-MS
07:34

Large Scale Non-targeted Metabolomic Profiling of Serum by Ultra Performance Liquid Chromatography-Mass Spectrometry UPLC-MS

Published on: March 14, 2013

12.8K

Analysis of non-targeted serum metabolomics in patients with chronic kidney disease and hyperuricemia

Wen-Yu Yang1, Jun Wang1, Xiao-Han Li2

  • 1College of Medical Technology, Chengdu University of Traditional Chinese Medicine, Chengdu, China.

Biotechnology & Genetic Engineering Reviews
|April 26, 2023
PubMed

Insights

Hyperuricemia (HUA) worsens chronic kidney disease (CKD) progression through unclear molecular mechanisms. This study reveals significant metabolic disruptions in HUA-CKD patients, indicating a more severe condition and providing a basis for understanding HUA

Area of Science:

  • Metabolomics
  • Nephrology
  • Biochemistry

Background:

  • Hyperuricemia (HUA) is a common complication of chronic kidney disease (CKD).
  • HUA is known to promote CKD progression, but the underlying molecular mechanisms are not fully understood.
  • Understanding these mechanisms is crucial for developing targeted therapies.

Purpose of the Study:

  • To investigate the molecular mechanisms of HUA in CKD development.
  • To compare serum metabolite profiles in patients with HUA-CKD, non-hyperuricemic CKD (NUA-CKD), and HUA.
  • To identify key metabolic pathways and biomarkers associated with HUA-induced CKD progression.

Main Methods:

  • Serum samples were collected from 47 HUA patients, 41 NUA-CKD patients, and 51 HUA-CKD patients.
  • Ultra-performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS) was used for serum metabolite profiling.
  • Multivariate statistical analysis, metabolic pathway analysis, and diagnostic performance evaluation were performed.

Main Results:

  • 40 differential metabolites were identified between HUA-CKD and HUA patients (FC > 1.5, VIP > 1, p < 0.05).
  • 24 differential metabolites were identified between HUA-CKD and NUA-CKD patients (FC > 1.2, VIP > 1, p < 0.05).
  • Glycerophospholipid metabolism was identified as a significantly altered pathway in HUA-CKD patients, indicating more severe metabolic disorders compared to NUA-CKD or HUA alone.

Conclusions:

  • Metabolic disorders in HUA-CKD patients are more severe than in NUA-CKD or HUA patients.
  • Significant alterations in metabolic pathways, particularly glycerophospholipid metabolism, are associated with HUA-CKD.
  • This study provides a theoretical basis for understanding how HUA accelerates CKD progression.

Keywords:
Chronic kidney diseasehyperuricemianon-targeted metabolomicsserumultra high-performance liquid chromatography-tandem mass spectrometry

More Related Videos

Identification and Quantification of Deranged Metabolites in Critically Ill Patients Using NMR-Based Metabolomics11:02

Identification and Quantification of Deranged Metabolites in Critically Ill Patients Using NMR-Based Metabolomics

Published on: November 29, 2024

597
Using a Chemical Biopsy for Graft Quality Assessment05:00

Using a Chemical Biopsy for Graft Quality Assessment

Published on: June 17, 2020

5.3K

Related Concept Videos

Serum Studies: Renal Function Tests01:24

Serum Studies: Renal Function Tests

Renal function tests are crucial for assessing kidney health, monitoring disease progression, and evaluating the kidneys' efficiency in waste elimination, fluid balance, and electrolyte regulation. These tests offer critical insights into kidney function, even though routine measurements may appear normal until there is a significant decline in the glomerular filtration rate or GFR. Typically, signs of kidney impairment only become evident when the GFR falls to about 50% of its normal level.
25
Chronic Kidney Disease III: Interprofessional Care01:28

Chronic Kidney Disease III: Interprofessional Care

Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
57
Factors Affecting Renal Clearance: Renal Impairment01:17

Factors Affecting Renal Clearance: Renal Impairment

Renal dysfunction significantly impairs the renal clearance of drugs, leading to potential complications in drug therapy. Renal failure, which can be caused by various factors, poses a significant challenge in the elimination of drugs from the body.
One condition associated with renal failure is uremia. Uremia is characterized by impaired glomerular filtration and fluid accumulation in the body. This condition hinders the renal clearance of drugs, resulting in drug accumulation and potential...
125
Chronic Kidney Disease II: Clinical Manifestations01:24

Chronic Kidney Disease II: Clinical Manifestations

Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...
47
Chronic Kidney Disease I: Introduction01:25

Chronic Kidney Disease I: Introduction

Chronic Kidney Disease (CKD) arises when the kidneys progressively lose their ability to function, ultimately leading to end-stage renal disease. At this advanced stage, the kidneys can no longer filter waste or maintain essential body functions, requiring renal replacement therapy (RRT) through dialysis or a kidney transplant for survival.Early-stage chronic kidney disease and detection challengesIn CKD's early stages, symptoms often remain absent because healthy nephrons compensate for...
49
Nephrotic Syndrome II : Assessment and Medical Management01:26

Nephrotic Syndrome II : Assessment and Medical Management

IntroductionNephrotic syndrome is a kidney disorder marked by excessive protein loss in the urine, leading to various systemic complications. This condition often results from damage to the glomeruli—the kidney's filtering units—causing proteinuria, low blood protein levels, and fluid retention. Understanding the assessment, diagnosis, and management of nephrotic syndrome is essential for effective treatment and prevention of further kidney damage.AssessmentPatient History: Document...
11